During the past three years, LINCC (TM) funding has focused on the country's most at-risk populations for HIV infection according to the Centers for Disease Control and Prevention[sup.
We're proud that for the third year in row, the LINCC (TM) Initiative carries on our commitment to help improve access to care and health outcomes, while also addressing healthcare disparities among the HIV community.
About the LINCC (TM) Initiative Programs funded through the LINCC (TM) Initiative focus on improving access to care, optimizing health outcomes and reducing HIV-related health disparities, particularly in underserved communities.
The LINCC Initiative extends the Janssen Therapeutics tradition of funding endeavors that address areas of significant unmet need in the HIV/AIDS community, while at the same time providing private sector funding to community-based organizations that are working to fulfill the goals of the National HIV/AIDS Strategy.
This LINCC Initiative is the fourth annual funding project for Janssen Therapeutics.
Tibotec Therapeutics is continuing its commitment to women by allocating half of the funding from the LINCC Initiative to programs focusing specifically on women and their unique barriers to care.
The LINCC Initiative also extends Tibotec Therapeutics' tradition of funding endeavors that address areas of significant unmet need in the HIV/AIDS community.